UniversitÉ De Lausanne

Luxembourg Institute of Health

The University Hospital of Lausanne

The Cardinal Stefa Wuszynski Institute of Cardiology

Firalis Sa

Samir Ounzain

Thierry Pedrazzini

Hueseyin Firat

Eric Schordan

Yvan Devaux

Lu Zhang

Przemyslaw Leszek

Sabrina Danilin

The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

This invention generally relates to lncRNAs and methods for diagnosing cardiac pathologies in a subject. The invention also provides methods for treating a cardiac pathology in a subject comprising administering to said subject an effective amount of a modulator of one or more lncRNAs of the invention.

Diagnostic, prognostic and therapeutic uses of long noncoding RNAS for heart disease and regenerative medicine

Growing community of inventors

Lausanne, Switzerland

Samir Ounzain